Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of NNC0519-0130 in Participants With Various Degrees of Renal Function
NCT06370819Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NNC0519-0130 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity. Started Apr 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06370819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370819.